smoking on glp 1 and IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target 8 Benefits of GLP‑1's Beyond

In the phase 3 ACHIEVE-3 trial , adults with type 2 diabetes inadequately controlled by metformin were randomized to receive orforglipron or oral semaglutide (7 mg and 14 mg, doses approved for type 2 diabetes)

This cytoprotective effect is mediated by PI3K and partially dependent on ERK1/2 and seems to be glucose-independent

Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network Pharmacology

Studies are needed for older people with sarcopenia but also for those at risk of sarcopenia

doi: 10.31202/ecjse.963670 215

It is a metabolic organ, a glucose sink, a functional reserve, and a major determinant of independence with aging